Oryzon Genomics Stock Price, News & Analysis
Company Description
Oryzon Genomics (OTC Link: ORYZF) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $254.2M.
ORYZF stock has gained 22.1% over the past year. Shares last traded at $3.70.
This page provides a comprehensive overview of ORYZF stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Oryzon Genomics (ORYZF) stock last traded at $3.70. Over the past 12 months, the stock has gained 22.1%. At a market capitalization of $254.2M, ORYZF is classified as a micro-cap stock with approximately 77.5M shares outstanding.
Latest News
Oryzon Genomics has 10 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 1 with negative movement. Key topics include clinical trial, fda approval. View all ORYZF news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Oryzon Genomics (ORYZF) currently stands at 5.6 thousand shares, up 1000.0% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has increased by 198.8%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Oryzon Genomics (ORYZF) currently stands at 4.0 days, down 99.6% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has decreased 99.6% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
ORYZF Company Profile & Sector Positioning
Oryzon Genomics (ORYZF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing ORYZF often look at related companies in the same sector, including Hansa Medical AB (HNSBF), Silence Therapeutics Plc (SLNCF), Bioinvent Intern (BOVNF), Nervgen Pharma Corp (NGENF), and Adocia (ADOCY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ORYZF's relative position within its industry.